Virtual Screening of FDA-Approved Compounds: Exploring New Alternatives for HIV Treatment

Area of Science:

• Computational chemistry and drug discovery
• Virology and infectious diseases
• Pharmacology and medicinal chemistry

Background:

• Human immunodeficiency virus (HIV) infection poses a significant global health threat.
• The rise of drug-resistant strains complicates highly active antiretroviral therapy (HAART).
• Novel therapeutic agents are essential to combat evolving HIV resistance.

Purpose of the Study:

• To identify novel drug candidates for HIV treatment through virtual screening.
• To leverage existing Food and Drug Administration (FDA)-approved drugs for repurposing.
• To validate computational methods for accelerating drug discovery.

Main Methods:

• Development and validation of quantitative structure-activity relationship (QSAR) models using high-throughput screening (HTS) data.
• Virtual screening of an FDA-approved drug library against HIV targets.
• Molecular docking and pharmacokinetic property predictions for promising candidates.

Main Results:

• Identification of a set of molecules with potential therapeutic activity against HIV.
• Demonstration of QSAR models' efficacy in predicting drug activity.
• Successful application of virtual screening for drug repurposing.

Conclusions:

• Virtual screening combined with QSAR modeling is an effective strategy for discovering new HIV therapeutics.
• Repurposing FDA-approved drugs offers a promising avenue for combating drug-resistant HIV.
• The identified compounds warrant further preclinical investigation for HIV treatment.